- Home
- UTHR vs QXO Comparison
UTHR vs QXO Comparison
Compare UTHR & QXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- QXO
- Stock Information
- Founded
- UTHR 1996
- QXO 1988
- Country
- UTHR United States
- QXO United States
- Employees
- UTHR N/A
- QXO N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- QXO EDP Services
- Sector
- UTHR Health Care
- QXO Technology
- Exchange
- UTHR Nasdaq
- QXO Nasdaq
- Market Cap
- UTHR 20.7B
- QXO 13.2B
- IPO Year
- UTHR 1999
- QXO N/A
- Fundamental
- Price
- UTHR $475.96
- QXO $16.75
- Analyst Decision
- UTHR Buy
- QXO Strong Buy
- Analyst Count
- UTHR 12
- QXO 12
- Target Price
- UTHR $495.08
- QXO $33.45
- AVG Volume (30 Days)
- UTHR 561.7K
- QXO 7.8M
- Earning Date
- UTHR 10-29-2025
- QXO 11-06-2025
- Dividend Yield
- UTHR N/A
- QXO N/A
- EPS Growth
- UTHR 16.08
- QXO N/A
- EPS
- UTHR 26.38
- QXO N/A
- Revenue
- UTHR $3,128,400,000.00
- QXO $4,662,873,000.00
- Revenue This Year
- UTHR $13.68
- QXO $12,779.57
- Revenue Next Year
- UTHR $5.63
- QXO $56.23
- P/E Ratio
- UTHR $18.07
- QXO N/A
- Revenue Growth
- UTHR 13.50
- QXO 8107.98
- 52 Week Low
- UTHR $266.98
- QXO $11.85
- 52 Week High
- UTHR $485.32
- QXO $24.69
- Technical
- Relative Strength Index (RSI)
- UTHR 70.75
- QXO 39.71
- Support Level
- UTHR $444.04
- QXO $15.50
- Resistance Level
- UTHR $464.27
- QXO $19.37
- Average True Range (ATR)
- UTHR 12.45
- QXO 0.93
- MACD
- UTHR 2.18
- QXO 0.00
- Stochastic Oscillator
- UTHR 84.68
- QXO 32.17
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About QXO QXO Inc. Common Stock
QXO Inc is a building products distribution company engaged in the distribution of roofing, waterproofing and complementary building products in North America. It offers a full suite of business applications, including ERP, warehouse management, accounting, CRM, and business intelligence solutions.